Association of COMT Val<sup>108/158</sup>Met Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial

Elaine C. Johnstone,1 Katherine M. Elliot,1 Sean P. David,3 Michael F.G. Murphy,2 Robert T. Walton,1,4 and Marcus R. Munafo5

1Department of Clinical Pharmacology and 4Childhood Cancer Research Group, University of Oxford, Oxford, United Kingdom; 2The Warren Alpert Medical School of Brown Medical School and Memorial Hospital of Rhode Island, Rhode Island; 3Medical Research Council Laboratories, Banjul, Gambia; and 5Department of Experimental Psychology, University of Bristol, Bristol, United Kingdom

Abstract

We investigated the association of catechol-O-methyltransferase (COMT) genotype with abstinence following a smoking cessation attempt among a large cohort of smokers who attempted to quit using either the nicotine transdermal patch or placebo and were followed up over an 8-year period following their initial cessation attempt. In addition, we examined the possible moderating influence of sex on any association. The genotype x treatment interaction effect at 12-week follow-up indicated a greater benefit of active nicotine replacement treatment compared with placebo on likelihood of abstinence in the COMT Met/Met genotype group (33% versus 12%), in comparison to the Met/Val + Val/Val group (22% versus 16%). Our results indicate that COMT genotype may moderate the effect of active transdermal nicotine patch compared with placebo, with reduced relative benefit of nicotine replacement therapy in individuals with Met/Val or Val/Val genotype. Our data follow an emerging pattern of results suggesting that genetic variation in the dopamine pathway may provide a future basis for tailored smoking cessation therapies, but indicate that different genes influencing various components of this pathway may have different effects on response to smoking cessation pharmacotherapy. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1065–9)

Introduction

Over 1 billion people worldwide continue to smoke cigarettes (1), and it is estimated that 500 million people alive today will be killed by smoking (2). Although many smokers report a desire to quit, only a small number embark on a cessation attempt in any given year (3). The majority of those that do attempt to quit eventually relapse to smoking, most within 12 months or less of the cessation attempt (3). Smoking behavior is known to be under a degree of genetic influence (4). Pharmacogenetic research has a number of aims, including to determine whether the efficacy of different pharmacotherapies for the treatment of nicotine dependence is influenced by inherited variation in drug-metabolizing enzymes and drug targets (5, 6). To date, two pharmacogenetic trials of nicotine replacement therapy (NRT) have been conducted (7-13).

Based on the neurobiology of reward (14), several pharmacogenetic analyses have focused on genes in the dopamine pathway (7, 8, 11, 15, 16). Nicotine is the main addictive component of tobacco smoking and stimulates the release of dopamine in the nucleus accumbens, which is partly responsible for its reinforcing effects (17, 18). Polymorphisms in genes in the dopamine pathway are therefore strong candidates for influencing smoking behavior phenotypes, including smoking cessation and treatment response. The enzyme catechol-O-methyltransferase (COMT) is of relevance in pharmacogenetic studies of nicotine dependence and treatment outcome due to its presence in dopaminergic brain regions and its role as a key enzyme in the degradation and inactivation of extraneuronally released dopamine (19, 20). The Val<sup>108/158</sup>Met polymorphism is located on exon 3 of the COMT gene (rs4680) and is a G1947A transition that results in the substitution of a valine (Val, G) by a methionine (Met, A; ref. 21) at codon 108/158, for S-COMT and MB-COMT, respectively (22). The Met (A) allele confers low activity of the gene, resulting in a 3- to 4-fold reduction in COMT enzyme activity (23), which is hypothesized to result in relatively greater dopamine activity as a result of reduced inactivation with lower enzyme activity (23).

Two recent investigations have shown a positive association with COMT genotype and smoking behavior, but only in women. Colilla et al. (16) found that women who were homozygous for the low-activity Met allele were significantly more likely to be abstinent from smoking at the end of a period of NRT. Another recent study by Beuten et al. (24) found that a COMT haplotype, including the Val<sup>108/158</sup>Met polymorphism, had a significant association with nicotine dependence, conferring protection in females but not males. However, a number of studies have failed to show any association between COMT genotype and tobacco consumption (25), and smoking initiation, persistence, and cessation (26). An evaluation of nonreplicated results involving COMT and nicotine dependence was carried out by Redden et al. (27). The authors critically reviewed two contradicting studies, analyzing oftencited reasons for nonreplication, such as type 1 error, low...
statistical power, and population stratification. Although they found no definitive answer, they concluded that the failure to replicate the results from the first study was likely to be due either to low statistical power to detect a small effect, or the effect of heterogeneity.

The evidence that the association of COMT genotype with smoking behavior may differ in males and females (16, 24) is consistent with evidence for individual differences in COMT activity in males and females, which is mediated by differences in estrogen metabolism. COMT is involved in the breakdown of catechol estrogens to estrone (28). Estrogen is also a regulator of COMT promoter activity (29), and COMT activity is lower in the brain (19) and blood (30) of women, due to inactivation by estrogen. Therefore, any effect of COMT genotype on smoking cessation may vary between women and men due to this sex-specific difference in COMT activity. There is also growing wider interest in sex differences in smoking cessation and treatment response, although the evidence is somewhat conflicting (31).

To the best of our knowledge, no studies to date have investigated COMT genotype and smoking cessation among treatment-seeking smokers using NRT. We therefore investigated the association of COMT genotype with abstinence following a smoking cessation attempt among a large cohort of smokers who attempted to quit using either the NRT transdermal patch or placebo and were followed up over an 8-year period following their initial cessation attempt. In addition, we examined the possible moderating influence of sex on any association.

### Materials and Methods

**Participants.** Participants in the original study included \( N = 1,686 \) patients from general practice (GP) surgeries in Oxfordshire, United Kingdom, who participated in a double-blind, randomized, placebo-controlled trial of the nicotine transdermal patch between June 1991 and March 1992 (the Patch study; refs. 32, 33). The inclusion criteria for this study were that participants smoked at least 15 cigarettes a day and were aged between 25 and 65 years.

In 1999 to 2000, participants were recontacted and invited to enter the study. Of the \( N = 1,686 \) participants enrolled in the Patch study, \( n = 154 \) subjects were unavailable because they could not be located (moved, emigrated, or untraceable) or were deceased. Invitation letters were sent to the remaining \( n = 1,532 \) participants, and those interested in joining the study were given an appointment with a nurse at each participant’s GP surgery, during which a short questionnaire was given and a 10-mL blood sample was collected. Blood samples were successfully collected on \( n = 755 \) (49%) participants. The methods for recruitment, allocation, and randomization of the Patch (32, 33), and the 8-year follow-up (Patch II) studies (7, 11, 32, 33) have been comprehensively described.

**Treatment.** In the Patch study, participants were randomly assigned to wear active nicotine or placebo patches for 12 weeks by prior random allocation of study numbers to each intervention group and sequential allocation of a study number to participants on entry. Participants were assessed by a study nurse at 1, 4, 8, 12, 26, and 52 weeks. Active and placebo patches were identical as prepared by the manufacturer, and all investigators and patients were blinded to treatment allocation. The main outcome measure was self-reported abstinence, which was confirmed with salivary cotinine and exhaled carbon monoxide (CO) measurement.

Ethical approval was obtained from the Anglia and Oxford Multicentre Research Ethics Committee and from the 86 Local Research Ethics Committees covering the areas of residence of the participants in the Patch study.

**Abstinence Verification.** Abstinence at 1, 4, and 8 weeks was confirmed by an expired CO reading \( \leq 10 \) ppm and at 12, 26, and 52 weeks by a salivary cotinine level \( \leq 20 \) ng/mL (89% of cases) or expired CO reading \( \leq 10 \) ppm. Saliva cotinine was assayed by gas chromatography in the Department of Preventive Medicine at St. Bartholomew’s Medical College (London, United Kingdom).

**Genotyping.** Participants were genotyped for the COMT Val108/158Met G1947A polymorphism using methods described in detail elsewhere (25) and briefly here. PCR was carried out using an allele-specific, two-tube primer method. The reaction mixture contained 0.7 \( \mu \)mol/L of each COMT primer, sequences ATGGTTGATTTCGTGCGG and ATGGTGGATTTCGCTGCG for the common reverse, 0.3 \( \mu \)mol/L of each control primer, \(-25\) ng of DNA, 300 \( \mu \)mol/L deoxynucleotide triphosphates, 1.5 mmol/L MgCl2, and 0.1 units of Taq polymerase in a final volume of 10 \( \mu \)L. After an initial denaturation step for 1 min at 96°C, thermocycling consisted of 5 cycles of 96°C for 20 s, 70°C for 45 s, 72°C for 25 s, followed by 21 cycles of 96°C for 25 s, 65°C for 30 s, 72°C for 30 s, then 4 cycles of 96°C for 30 s, 55°C for 60 s, and 72°C for 90 s. A final step of 20°C for 5 min was followed by cooling of samples to 4°C. PCR products were separated on a 1% agarose gel at 200 V for 24 min and visualized using ethidium bromide. In order for samples to be valid, a 350-bp product was present in one of the reactions. A homozygote was indicated by the presence of a 350-bp product in one of the reactions, and a heterozygote was represented by a 350-bp product in both of the reactions.

**Statistical Analysis.** Biochemically verified point-prevalence 7-day abstinence, at 12-week (end of treatment; EOT) and 26-week follow-up, were the primary outcome measures. Participants lost to follow-up were assumed to have relapsed to smoking and coded as such in outcome analyses (i.e., intent to treat analyses).

Separate models of outcome at 12-week and 26-week follow-up were generated within a logistic regression framework because pharmacotherapy was available only during the treatment phase. The full models included age, sex, socioeconomic status, and nicotine dependence at baseline in the first step, treatment group (active patch, placebo patch) and COMT genotype (Met/Met, Met/Val + Val/Val) in the second step, and interaction terms for treatment \( \times \) sex, treatment \( \times \) genotype, sex \( \times \) genotype, and treatment \( \times \) sex \( \times \) genotype in the third step. Terms were entered using the backward conditional method, with term removal conditional on \( P > 0.10 \), with the exception of main effects of treatment and genotype which were entered using the enter method. COMT Met/Val and Val/Val genotypes were combined to increase statistical power and given evidence for recessive effects on functional activity (23).

All analyses were done using the Statistical Package for the Social Sciences (v. 12.0). An \( \alpha \) level of 0.05 was maintained throughout the analysis.

**Statistical Power.** Of the \( n = 724 \) participants in the final study population, \( n = 363 \) received active patch, and \( n = 361 \) received placebo patch. The sample size was adequate to detect a risk ratio of 1.6 at 12-week follow-up and 1.8 at 26-week follow-up, with a power of 0.80, for a main effect of genotype on cessation.
Results

Characteristics of Participants. Of the \( n = 749 \) participants who were successfully genotyped for the \( COMT \) Val108/158Met G1947A polymorphism, we retained \( n = 741 \) of European ancestry to avoid potential population stratification. There were missing data on \( n = 17 \) participants, resulting in a final sample for analysis of \( n = 724 \) smokers (59% female) of European ancestry. The mean age of participants was 43 years (SD, 10; range, 25-65). Participants were older than non-participants (\( M = 43 \) years versus \( M = 42 \) years; \( P = 0.002 \)), more likely to be female (59% versus 53%; \( P = 0.010 \)) and more likely to have quit for a year in the trial (14% versus 6%; \( P < 0.001 \)). There was no difference in the frequency of abstinence from smoking between the genotype groups at either follow-up (12-week, \( P = 0.25 \); 26-week, \( P = 0.87 \)). \( COMT \) genotype frequencies did not deviate significantly from Hardy-Weinberg Equilibrium (\( P = 0.46 \)).

Analysis of Smoking Cessation Outcomes. The main effect of treatment was significant at 12-week (\( P < 0.001 \)) and 26-week (\( P = 0.004 \)) follow-up, indicating an increased likelihood of abstinence on active NRT relative to placebo, as previously reported (32, 33). There was evidence for a genotype \( \times \) treatment interaction effect at 12-week follow-up (\( P = 0.050 \)), but this term was not significant at 26-week follow-up and not retained in the model, and a Z test indicated that the interaction effect at 26-week follow-up differed significantly from that at 12-week follow-up (\( Z = 21.87, P < 0.001 \)). Age was positively associated with the likelihood of abstinence at 12-week (\( P = 0.013 \)) and 26-week (\( P = 0.010 \)) follow-up. Higher SES was marginally associated with an increased likelihood of abstinence at 12-week follow-up (\( P = 0.090 \)), but was not retained in the model at 26-week follow-up. Finally, nicotine dependence was not retained in the model at 12-week follow-up but was included at 26-week follow-up, indicating a trend for lower dependence to be associated with an increased likelihood of abstinence at 26-week follow-up (\( P = 0.085 \)). The main effect of genotype was not significant at either 12-week (\( P = 0.333 \)) or 26-week (\( P = 0.914 \)) follow-up. No main effects or interaction terms involving sex were retained in either model.

The significant genotype \( \times \) treatment interaction effect at 12-week follow-up indicated a greater benefit of active NRT treatment compared with placebo on likelihood of abstinence in the \( COMT \) Met/Met genotype group (33% versus 12%), in comparison to the Met/Val + Val/Val group (22% versus 16%). These data are presented graphically in Fig. 1.

Discussion

Our results indicate that \( COMT \) genotype may moderate the effect of active transdermal nicotine patch compared with placebo. We observed a greater benefit of active NRT treatment compared with placebo on the likelihood of abstinence in the \( COMT \) Met/Met genotype group, in comparison to those in either the Met/Val or Val/Val groups. These effects were only observed at 12-week follow-up (EOT), which suggests that this represents a short-term pharmacogenetic effect. This effect attenuated and was no longer significant at 26-week follow-up and did not seem to differ between males and females.

A recent study represents the only previous pharmacogenetic study of \( COMT \) genotype and smoking cessation. Berrettini et al. (15) found that a \( COMT \) haplotype of two single nucleotide polymorphisms (including Val108/158Met) predicted favorable outcome of bupropion pharmacotherapy for smoking cessation, although no differences in this

Table 1. Demographic characteristics and \( COMT \) genotype frequency by treatment condition

<table>
<thead>
<tr>
<th></th>
<th>Active (( n = 363 ))</th>
<th>Placebo (( n = 361 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y), M ± SD</td>
<td>42 ± 10</td>
<td>43 ± 10</td>
</tr>
<tr>
<td>Sex (male), n (%)</td>
<td>152 (42)</td>
<td>144 (40)</td>
</tr>
<tr>
<td>Socioeconomic status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–professional</td>
<td>11 (3)</td>
<td>8 (2)</td>
</tr>
<tr>
<td>II–managerial</td>
<td>112 (31)</td>
<td>117 (33)</td>
</tr>
<tr>
<td>IIIa–nonmanual</td>
<td>86 (24)</td>
<td>75 (21)</td>
</tr>
<tr>
<td>IIIb–manual</td>
<td>75 (21)</td>
<td>17 (7)</td>
</tr>
<tr>
<td>IV–semskilled</td>
<td>65 (17)</td>
<td>58 (16)</td>
</tr>
<tr>
<td>V–unskilled</td>
<td>16 (4)</td>
<td>26 (7)</td>
</tr>
<tr>
<td>Nicotine dependence, M ± SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M = 15 ± 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMT genotype, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Met/Met</td>
<td>114 (31)</td>
<td>109 (30)</td>
</tr>
<tr>
<td>Met/Val</td>
<td>165 (46)</td>
<td>166 (46)</td>
</tr>
<tr>
<td>Val/Val</td>
<td>84 (23)</td>
<td>86 (24)</td>
</tr>
</tbody>
</table>

NOTE: Baseline measures do not differ significantly between the active and placebo groups (\( P > 0.28 \).)

Cancer Epidemiol Biomarkers Prev 2007;16(6). June 2007

Downloaded from cebp.aacrjournals.org on October 13, 2017. © 2007 American Association for Cancer Research.
Our results indicate that COMT genotype may moderate the effect of active transdermal nicotine patch compared with placebo, with reduced benefit of standard NRT in individuals with either Met/Val or Val/Val genotypes. Further studies are needed to examine possible biobehavioral mechanisms that may mediate our observed genotype × treatment interaction, to provide biological plausibility for these data. In addition, replication will be required before the association identified in our data can be considered to be robust. Future studies should also seek to examine potential interactions between genotype and sex with adequate sample size to afford sufficient power to detect higher level interactions. However, these results do follow an emerging pattern of results, suggesting that genetic variation in the dopamine pathway may provide a future basis for tailored smoking cessation therapies (5, 6).

References


Table 2. Logistic regression models of abstinence at 12-wk and 26-wk follow-up

<table>
<thead>
<tr>
<th></th>
<th>12-wk follow-up OR (95% CI)</th>
<th>P</th>
<th>26-wk follow-up OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.02 (1.00-1.04)</td>
<td>0.013</td>
<td>1.03 (1.01-1.05)</td>
<td>0.010</td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td>0.88 (0.76-1.02)</td>
<td>0.090</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotine dependence*</td>
<td>0.96 (0.92-1.00)</td>
<td>0.085</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>3.53 (1.75-7.13)</td>
<td>&lt;0.001</td>
<td>1.81 (1.21-2.72)</td>
<td>0.004</td>
</tr>
<tr>
<td>COMT* genotype</td>
<td>1.37 (0.70-2.69)</td>
<td>0.353</td>
<td>0.98 (0.64-1.50)</td>
<td>0.914</td>
</tr>
<tr>
<td>COMT* × treatment</td>
<td>0.43 (0.19-1.00)</td>
<td>0.050</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Covariates controlled for in the model included age, sex, socioeconomic status, and nicotine dependence. Only those terms retained in the models are presented. Interaction terms for COMT × sex, treatment × sex, and COMT × sex × treatment were not retained in the model for any follow-up assessments. Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.

*Nicotine dependence measured using the Horn-Russell Scale (38).

Reference group is Met/Met.


Association of COMT Val108/158Met Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial

Elaine C. Johnstone, Katherine M. Elliot, Sean P. David, et al.


Updated version Access the most recent version of this article at: http://cebp.aacrjournals.org/content/16/6/1065

Cited articles This article cites 37 articles, 7 of which you can access for free at: http://cebp.aacrjournals.org/content/16/6/1065.full#ref-list-1

Citing articles This article has been cited by 4 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/16/6/1065.full#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.